Document is current
Any future updates will be listed below
-
Authors
Wang, Haiying
Tsao, Shih-Ting
Gu, Mingyuan
Fu, Chengbing
He, Feng
Li, Xiu
Zhang, Mian
Li, Na
Hu, Hong-Ming https://orcid.org/0000-0002-2206-3470
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03798509 at ClinicalTrials.govnct03720457 at ClinicalTrials.govDocuments that mention this clinical trial
A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
https://doi.org/10.1186/s12967-022-03833-6
nct04003168 at ClinicalTrials.govDocuments that mention this clinical trial
A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
https://doi.org/10.1186/s12967-022-03833-6
Documents that mention this clinical trial
A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
https://doi.org/10.1186/s12967-022-03833-6
-
Funding
Funding for this research was provided by:
Hrain Biotechnology Co., Ltd.
- License Information
-
More Information
Article History
Received: 4 November 2022
Accepted: 14 December 2022
First Online: 19 December 2022
Declarations
:
: Research involving human material has been performed by the Declaration of Helsinki. All patients provided written informed consent before the beginning of the clinical trials mentioned in this study. The ethical committee approved the study of Hrain Biotechnology Co., Ltd.
: Not applicable.
: H-MH was hired full-time by Hrain Biotechnology Co., Ltd. HW, S-TT, MG, CF, XL, MZ, NL, and FH are employed full-time by Hrain Biotechnology Co., Ltd. H-MH, HW, S-TT and MG have pending patents on CAR products developed at Hrain Biotechnology Co., Ltd.
